Global Radiopharmaceutical Market Research Report - Forecast to 2023

Global Radiopharmaceutical Market Analysis and Forecast 2023

Radiopharmaceuticals are those radioisotopes when used for diagnosis or therapy, typically stimulate no physiological response from the patient. They are the unique medicinal formulations containing radioisotopes which can be used diagnosis and treatment of various chronic diseases. Radioisotopes play a very crucial part in the medical diagnostic procedures. In combination with imaging devices which record the gamma rays emitted from inside, healthcare professionals can study the dynamic processes taking place in various parts of the body.

The increasing prevalence of chronic diseases which indicates the growing need for early diagnosis and treatment is one of the major factors responsible for the growth of the market. Moreover, rising expenditure in oncology and the growing emphasis on cancer management has also accelerated the market growth owing to the need for new diagnostic and treatment options for common as well as rare cancers.

Both diagnostic & treatment characteristics of radiopharmaceutical driving the market growth. As per the World Nuclear Association, in a quarter of the world population, about one person in 50 uses diagnostic nuclear medicine each year, and the frequency of therapy with radioisotopes is about one-tenth of this. Nuclear medicine uses radiation to provide diagnostic information about the functioning of a persons specific organs and used to treat some medical conditions, especially cancer, using radiation to weaken or destroy particular targeted cells.

Increasing Prevalence of Chronic Diseases is also driving the growth of the market. According to the World Cancer Research Fund International, in 2015, cancer was responsible for 8.8 million deaths and is the second leading cause of death across the globe. As per the American Heart Association, in 2017, about 92.1 million Americans were diagnosed with cardiovascular disease. Additionally, as per the National Research University Higher School of Economics, tension-type headaches (about 1,500 million cases), migraine (about 1,000 million), medication overuse headaches (about 60 million), and Alzheimers disease and other dementias (about 46 million cases) are the most common type of neurological disorders in 2015.

Whereas certain factors such as the high cost of radiopharmaceuticals are restraining the growth of the market. As per National Research Universal (NRU), the cost of some nuclear medicine have increased by as much as 1,000 percent recently. Similarly, according to the research, the overall financial cost for the underutilized radiopharmaceutical materials due to canceled and rescheduled procedures for 142 patients was about 39,760 US dollar. The daily financial loss from these cancellations was between USD 560 to USD 1120.

The global radiopharmaceuticals market is expected to reach to the market value of USD 10,473.88 million by 2023 from USD 5,841.22 million in 2016 and have a CAGR of 8.7% during the forecast period, 2017–2023.

On the basis of type, the market for Radiopharmaceutical is segmented into diagnostic type radiopharmaceuticals and therapeutic type radiopharmaceuticals By type, the market for diagnostic type radiopharmaceuticals accounted for the largest market share in 2017.

On the basis of the type of tests, the market for Radiopharmaceutical is segmented into myocardial perfusion scan, lung scan, bone scan, white blood cell scan, gallium scan, renal nuclear medicine scan, parathyroid scans, hepatobiliary scans, cerebral perfusion scan, and others. By type of tests, the market for intermediate Radiopharmaceutical accounted for the largest market share in 2017.

The global Radiopharmaceutical, by application, is segmented into oncology, cardiology, neurology, urology, and others. By application, the market for Oncology accounted for the largest market share in 2017.

The global Radiopharmaceutical, by route of administration, is segmented into oral, intravenous and other routes of administration. The intravenous segment holds the largest market share in global Radiopharmaceutical, by route of administration.

On the basis of the route of administration, the global Radiopharmaceutical market is segmented into intravenous, intravitreal, and others. The intravitreal segment dominates the global Radiopharmaceutical market.

The global Radiopharmaceutical, on the basis of end-user, is segmented into hospitals, diagnostic centers, research institutes, and others. Hospitals hold the largest market share in the global Radiopharmaceutical market.

Key Players

The key players for the Radiopharmaceutical market are Bayer AG, Cardinal Health Inc., General Electric Company, Lantheus Medical Imaging, Inc., Siemens, Avid Radiopharmaceuticals, IBA Dosimetry and Others.

Study Objectives

• To provide historical and forecast revenue of the market segments and sub-segments with respect to – regional markets and their countries
• To provide insights into factors influencing and affecting the market growth
• To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
• To provide economic factors that influence the global Radiopharmaceutical market

Target Audience

• Pharmaceutical and Medical Device Industries
• Potential Investors
• Medical Research Institutes
• Key Executive (CEO and COO) and Strategy Growth Manager
• Research Companies

Key Findings

• The major market players in the global Radiopharmaceutical market are F Bayer AG, Cardinal Health Inc., General Electric Company, Lantheus Medical Imaging, Inc., Siemens, Avid Radiopharmaceuticals, IBA Dosimetry and Others.
• Siemens accounted for more than 13.2% share of the global Radiopharmaceutical Market
• Based on type of tests, Bone Scan segment accounts the largest market share which is expected to reach USD 2,513.68 million by 2023 from USD 1,470.34 million in 2016
• Based on application, the market for oncology is expected to reach USD 4,747.76 million by 2023
• Based on route of administration, intravenous segment was the largest segment in the year 2017 and is expected to reach USD 7,316.86 million by 2023 from USD 3,995.90 million in 2016
• On the basis of region, Asia pacific region is projected to be the fastest growing region, at a CAGR of 9.3% during the forecast period.


The report also covers regional analysis

Americas
• North America
o U.S.
o Canada
• South America

Europe
• Western Europe
o Germany
o France
o Italy
o U.K.
o Spain
o Rest of Western Europe
• Eastern Europe

Asia Pacific
o China
o Japan
o India
o Australia
o Republic of Korea
o Rest of Asia Pacific

The Middle East & Africa
• Middle East
• Africa


1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Scope of Study
3.2 Research Objective
3.3 Assumptions & Limitations
3.3.1 Assumptions
3.3.2 Limitations
3.4 Market Structure
4 Research Methodology
4.1 Primary Research
4.2 Secondary Research
4.3 Market Size Estimation
4.4 Forecast Model
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 All-rounder (Both diagnostic & treatment), characteristics of radiopharmaceutical driving
the market growth (35%)
5.2.2 Increasing Prevalence of Chronic Diseases (20%)
5.2.3 Increasing Expenditure on Oncology Medicine (25%)
5.2.4 Increasing use of radiopharmaceuticals for the diagnosis & treatment of chronic diseases in
the elderly population (20%)
5.3 Restraints
5.3.1 The high cost of radiopharmaceuticals (55%)
5.3.2 Side Effects of Radiation Exposure (45%)
5.4 Opportunity
5.4.1 Potential radioisotopes in the pipeline
6 Market Factor Analysis
6.1 Porter’s Five Forces Model
6.1.1 Bargaining Power of Suppliers
6.1.2 Bargaining Power of Buyers
6.1.3 Threat of New Entrants
6.1.4 Threat of Substitutes
6.1.5 Intensity of Rivalry
6.2 Value Chain Analysis
6.2.1 Research & Product Development
6.2.2 Manufacturing
6.2.3 Distribution & Sales
6.2.4 Post-Sales Monitoring
6.3 Procedure Numbers
7 Global Radiopharmaceutical Market, by Type
7.1 Introduction
7.1.1 Diagnostic Type
7.1.2 Therapeutic Type
8 Global Radiopharmaceuticals Market, by Type of Test
8.1 Introduction
8.1.1 Bone Scan
8.1.2 Myocardial Perfusion Scan
8.1.3 Parathyroid Scan
8.1.4 Renal Nuclear Medicine Scan
8.1.5 Lung Scan
8.1.6 Gallium Scan
8.1.7 White Blood Cell Scan
8.1.8 Hepatobiliary Scan
8.1.9 Cerebral Perfusion Scan
9 Global Radiopharmaceutical Market, by Application
9.1 Introduction
9.1.1 Oncology
9.1.2 Cardiology
9.1.3 Neurology
9.1.4 Urology
10 Global Radiopharmaceutical Market, by Route of Administration
10.1 Introduction
10.1.1 Oral
10.1.2 Intravenous
11 Global Radiopharmaceutical Market, by End-User
11.1 Introduction
11.1.1 Hospitals
11.1.2 Diagnostic Centers
11.1.3 Research Institutes
12 Global Radiopharmaceutical Market, by Region
12.1 Introduction
12.2 Americas
12.2.1 North America
12.2.1.1 U.S.
12.2.1.2 Canada
12.2.2 South America
12.3 Europe
12.3.1 Western Europe
12.3.1.1 Germany
12.3.1.2 France
12.3.1.3 U.K.
12.3.1.4 Italy
12.3.1.5 Spain
12.3.1.6 Rest of Western Europe
12.3.2 Eastern Europe
12.4 Asia Pacific
12.4.1 Japan
12.4.2 China
12.4.3 India
12.4.4 Australia
12.4.5 Republic of Korea
12.4.6 Rest of Asia Pacific
12.5 The Middle East & Africa
12.5.1.1 Middle East
12.5.1.2 Africa
13 Competitive Landscape
13.1 Company Market Share Analysis
13.1.1 Introduction
13.1.2 Company Share Analysis
13.2 Recent Developments, 2013–2018
14 Company Profile
14.1 Jubilant Life Sciences Ltd.
14.1.1 Company Overview
14.1.2 Financial Overview
14.1.3 Products Offerings
14.1.4 Key Developments
14.1.5 SWOT Analysis
14.1.6 Key Strategy
14.2 Siemens AG
14.2.1 Company Overview
14.2.2 Financial Overview
14.2.3 Products Offerings
14.2.4 Key Developments
14.2.5 SWOT Analysis
14.2.6 Key Strategy
14.3 Sun Pharmaceutical Industries Ltd.
14.3.1 Company Overview
14.3.2 Financial Overview
14.3.3 Products Offerings
14.3.4 Key Developments
14.3.5 SWOT Analysis
14.3.6 Key Strategy
14.4 Bayer AG
14.4.1 Company Overview
14.4.2 Financial Overview
14.4.3 Products Offerings
14.4.4 Key Developments
14.4.5 SWOT Analysis
14.4.6 Key Strategy
14.5 Cardinal Health Inc.
14.5.1 Company Overview
14.5.2 Financial Overview
14.5.3 Products Offerings
14.5.4 Key Developments
14.5.5 SWOT Analysis
14.5.6 Key Strategy
14.6 Medtronic
14.6.1 Company Overview
14.6.2 Financial Overview
14.6.3 Products Offerings
14.6.4 Key Developments
14.6.5 SWOT Analysis
14.6.6 Key Strategy
14.7 General Electric Company (GE Healthcare)
14.7.1 Company Overview
14.7.2 Financial Overview
14.7.3 Products Offerings
14.7.4 Key Developments
14.7.5 SWOT Analysis
14.7.6 Key Strategy
14.8 Lantheus Medical Imaging, Inc.
14.8.1 Company Overview
14.8.2 Financial Overview
14.8.3 Products Offerings
14.8.4 Key Developments
14.8.5 SWOT Analysis
14.8.6 Key Strategy
14.9 Advanced Accelerator Applications S.A.
14.9.1 Company Overview
14.9.2 Financial Overview
14.9.3 Products Offerings
14.9.4 Key Developments
14.9.5 SWOT Analysis
14.9.6 Key Strategy
14.10 Mallinckrodt Pharmaceuticals
14.10.1 Company Overview
14.10.2 Financial Overview
14.10.3 Products Offerings
14.10.4 Key Developments
14.10.5 SWOT Analysis
14.10.6 Key Strategy
14.11 Nordion, Inc.
14.11.1 Company Overview
14.11.2 Financial Overview
14.11.3 Products Offerings
14.11.4 Key Developments
14.11.5 SWOT Analysis
14.11.6 Key Strategy
14.12 Canadian Nuclear Laboratories (CNL)
14.12.1 Company Overview
14.12.2 Financial Overview
14.12.3 Products Offerings
14.12.4 Key Developments
14.12.5 SWOT Analysis
14.12.6 Key Strategy
14.13 Bracco Diagnostic Inc.
14.13.1 Company Overview
14.13.2 Financial Overview
14.13.3 Products Offerings
14.13.4 Key Developments
14.13.5 SWOT Analysis
14.13.6 Key Strategy
14.14 IBA Dosimetry GmbH
14.14.1 Company Overview
14.14.2 Financial Overview
14.14.3 Products Offerings
14.14.4 Key Developments
14.14.5 SWOT Analysis
14.14.6 Key Strategy
14.15 Avid Radiopharmaceuticals
14.15.1 Company Overview
14.15.2 Financial Overview
14.15.3 Products Offerings
14.15.4 Key Developments
14.15.5 SWOT Analysis
14.15.6 Key Strategy
15 Appendix
15.1 Discussion Blue Print


List Of Tables


TABLE 1 MARKET SYNOPSIS
TABLE 2 GLOBAL RADIOPHARMACEUTICAL MARKET, BY TYPE, 2014–2023 (USD MILLION)
TABLE 3 GLOBAL RADIOPHARMACEUTICAL MARKET FOR DIAGNOSTIC, BY TYPE, 2014–2023 (USD MILLION)
TABLE 4 GLOBAL RADIOPHARMACEUTICAL MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION)
TABLE 5 GLOBAL RADIOPHARMACEUTICAL MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION)
TABLE 6 GLOBAL RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC, BY TYPE, 2014–2023 (USD MILLION)
TABLE 7 GLOBAL RADIOPHARMACEUTICAL MARKET FOR BETA EMITTERS, BY TYPE, 2014–2023 (USD MILLION)
TABLE 8 GLOBAL RADIOPHARMACEUTICAL MARKET FOR BRACHYTHERAPY, BY TYPE, 2014–2023 (USD MILLION)
TABLE 9 GLOBAL RADIOPHARMACEUTICAL MARKET FOR DIAGNOSTIC TYPE, BY REGION, 2014–2023 (USD MILLION)
TABLE 10 GLOBAL RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC TYPE, BY REGION, 2014–2023 (USD MILLION)
TABLE 11 GLOBAL RADIOPHARMACEUTICALS MARKET, BY TYPE OF TEST, 2014–2023 (USD MILLION)
TABLE 12 GLOBAL RADIOPHARMACEUTICALS MARKET FOR BONE SCAN, BY TYPE, 2014–2023 (USD MILLION)
TABLE 13 GLOBAL RADIOPHARMACEUTICALS MARKET FOR MYOCARDIAL PERFUSION SCAN, BY TYPE, 2014–2023 (USD MILLION)
TABLE 14 GLOBAL RADIOPHARMACEUTICALS MARKET FOR LUNG SCAN, BY TYPE, 2014–2023 (USD MILLION)
TABLE 15 GLOBAL RADIOPHARMACEUTICALS MARKET FOR WHITE BLOOD CELL SCAN, BY TYPE, 2014–2023 (USD MILLION)
TABLE 16 GLOBAL RADIOPHARMACEUTICALS MARKET FOR BONE SCAN, BY REGION, 2014–2023 (USD MILLION)
TABLE 17 GLOBAL RADIOPHARMACEUTICALS MARKET FOR MYOCARDIAL PERFUSION SCAN, BY REGION, 2014–2023 (USD MILLION)
TABLE 18 GLOBAL RADIOPHARMACEUTICALS MARKET FOR PARATHYROID SCAN, BY REGION, 2014–2023 (USD MILLION)
TABLE 19 GLOBAL RADIOPHARMACEUTICALS MARKET FOR RENAL NUCLEAR MEDICINE SCAN, BY REGION, 2014–2023 (USD MILLION)
TABLE 20 GLOBAL RADIOPHARMACEUTICALS MARKET FOR LUNG SCAN, BY REGION, 2014–2023 (USD MILLION)
TABLE 21 GLOBAL RADIOPHARMACEUTICALS MARKET FOR GALLIUM SCAN, BY REGION, 2014–2023 (USD MILLION)
TABLE 22 GLOBAL RADIOPHARMACEUTICALS MARKET FOR WHITE BLOOD CELL SCAN, BY REGION, 2014–2023 (USD MILLION)
TABLE 23 GLOBAL RADIOPHARMACEUTICALS MARKET FOR HEPATOBILIARY SCAN, BY REGION, 2014–2023 (USD MILLION)
TABLE 24 GLOBAL RADIOPHARMACEUTICALS MARKET FOR CEREBRAL PERFUSION SCAN, BY REGION, 2014–2023 (USD MILLION)
TABLE 25 GLOBAL RADIOPHARMACEUTICAL MARKET, BY APPLICATION, 2014–2023 (USD MILLION)
TABLE 26 GLOBAL RADIOPHARMACEUTICAL MARKET FOR ONCOLOGY, BY TYPE, 2014–2023 (USD MILLION)
TABLE 27 GLOBAL RADIOPHARMACEUTICAL MARKET FOR CARDIOLOGY, BY TYPE, 2014–2023 (USD MILLION)
TABLE 28 GLOBAL RADIOPHARMACEUTICAL MARKET FOR NEUROLOGY, BY TYPE, 2014–2023 (USD MILLION)
TABLE 29 GLOBAL RADIOPHARMACEUTICAL MARKET FOR UROLOGY, BY TYPE, 2014–2023 (USD MILLION)
TABLE 30 GLOBAL RADIOPHARMACEUTICAL MARKET FOR ONCOLOGY, BY REGION, 2014–2023 (USD MILLION)
TABLE 31 GLOBAL RADIOPHARMACEUTICAL MARKET FOR CARDIOLOGY, BY REGION, 2014–2023 (USD MILLION)
TABLE 32 GLOBAL RADIOPHARMACEUTICAL MARKET FOR NEUROLOGY, BY REGION, 2014–2023 (USD MILLION)
TABLE 33 GLOBAL RADIOPHARMACEUTICAL MARKET FOR UROLOGY, BY REGION, 2014–2023 (USD MILLION)
TABLE 34 GLOBAL RADIOPHARMACEUTICAL MARKET, BY ROUTE OF ADMINISTRATION, 2014–2023 (USD MILLION)
TABLE 35 GLOBAL RADIOPHARMACEUTICAL MARKET FOR ORAL, BY REGION, 2014–2023 (USD MILLION)
TABLE 36 GLOBAL RADIOPHARMACEUTICAL MARKET FOR ORAL, BY REGION, 2014–2023 (USD MILLION)
TABLE 37 GLOBAL RADIOPHARMACEUTICAL MARKET, BY END-USER, 2014–2023 (USD MILLION)
TABLE 38 GLOBAL RADIOPHARMACEUTICAL MARKET FOR HOSPITALS, BY REGION, 2014–2023 (USD MILLION)
TABLE 39 GLOBAL RADIOPHARMACEUTICAL MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2014–2023 (USD MILLION)
TABLE 40 GLOBAL RADIOPHARMACEUTICAL MARKET FOR RESEARCH INSTITUTES, BY REGION, 2014–2023 (USD MILLION)
TABLE 41 GLOBAL RADIOPHARMACEUTICAL MARKET, BY REGION, 2014–2023 (USD MILLION)
TABLE 42 AMERICAS RADIOPHARMACEUTICAL MARKET, BY REGION, 2014–2023 (USD MILLION)
TABLE 43 AMERICAS RADIOPHARMACEUTICAL MARKET, BY TYPE, 2014–2023 (USD MILLION)
TABLE 44 AMERICAS RADIOPHARMACEUTICAL MARKET FOR DIAGNOSTIC, BY TYPE, 2014–2023 (USD MILLION)
TABLE 45 AMERICAS RADIOPHARMACEUTICAL MARKET FOR SPECT RADIOPHARMACEUTICALS, 2014–2023 (USD MILLION)
TABLE 46 AMERICAS RADIOPHARMACEUTICAL MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION)
TABLE 47 AMERICAS RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC, BY TYPE, 2014–2023 (USD MILLION)
TABLE 48 AMERICAS RADIOPHARMACEUTICAL MARKET FOR BETA EMITTERS, BY TYPE, 2014–2023 (USD MILLION)
TABLE 49 AMERICAS RADIOPHARMACEUTICAL MARKET FOR BRACHYTHERAPY, BY TYPE, 2014–2023 (USD MILLION)
TABLE 50 AMERICAS RADIOPHARMACEUTICALS MARKET, BY TYPE OF TEST, 2014–2023 (USD MILLION)
TABLE 51 AMERICAS RADIOPHARMACEUTICALS MARKET FOR BONE SCAN, BY TYPE, 2014–2023 (USD MILLION)
TABLE 52 AMERICAS RADIOPHARMACEUTICALS MARKET FOR MYOCARDIAL PERFUSION SCAN, BY TYPE, 2014–2023 (USD MILLION)
TABLE 53 AMERICAS RADIOPHARMACEUTICALS MARKET FOR LUNG SCAN, BY TYPE, 2014–2023 (USD MILLION)
TABLE 54 AMERICAS RADIOPHARMACEUTICALS MARKET FOR WHITE BLOOD CELL SCAN, BY TYPE, 2014–2023 (USD MILLION)
TABLE 55 AMERICAS RADIOPHARMACEUTICAL MARKET, BY APPLICATION, 2014–2023 (USD MILLION)
TABLE 56 AMERICAS RADIOPHARMACEUTICAL MARKET FOR ONCOLOGY, BY TYPE, 2014–2023 (USD MILLION)
TABLE 57 AMERICAS RADIOPHARMACEUTICAL MARKET FOR CARDIOLOGY, BY TYPE, 2014–2023 (USD MILLION)
TABLE 58 AMERICAS RADIOPHARMACEUTICAL MARKET FOR NEUROLOGY, BY TYPE, 2014–2023 (USD MILLION)
TABLE 59 AMERICAS RADIOPHARMACEUTICAL MARKET FOR UROLOGY, BY TYPE, 2014–2023 (USD MILLION)
TABLE 60 AMERICAS RADIOPHARMACEUTICAL MARKET, BY ROUTE OF ADMINISTRATION, 2014–2023 (USD MILLION)
TABLE 61 AMERICAS RADIOPHARMACEUTICAL MARKET, BY END-USER, 2014–2023 (USD MILLION)
TABLE 62 U.S. RADIOPHARMACEUTICAL MARKET, BY TYPE, 2014–2023 (USD MILLION)
TABLE 63 U.S. RADIOPHARMACEUTICAL MARKET FOR DIAGNOSTIC, BY TYPE, 2014–2023 (USD MILLION)
TABLE 64 U.S. RADIOPHARMACEUTICAL MARKET FOR Z, 2014–2023 (USD MILLION)
TABLE 65 U.S. RADIOPHARMACEUTICAL MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION)
TABLE 66 U.S. RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC, BY TYPE, 2014–2023 (USD MILLION)
TABLE 67 U.S. RADIOPHARMACEUTICAL MARKET FOR BETA EMITTERS, BY TYPE, 2014–2023 (USD MILLION)
TABLE 68 U.S. RADIOPHARMACEUTICAL MARKET FOR BRACHYTHERAPY, BY TYPE, 2014–2023 (USD MILLION)
TABLE 69 U.S. RADIOPHARMACEUTICALS MARKET, BY TYPE OF TEST, 2014–2023 (USD MILLION)
TABLE 70 U.S. RADIOPHARMACEUTICALS MARKET FOR BONE SCAN, BY TYPE, 2014–2023 (USD MILLION)
TABLE 71 U.S. RADIOPHARMACEUTICALS MARKET FOR MYOCARDIAL PERFUSION SCAN, BY TYPE, 2014–2023 (USD MILLION)
TABLE 72 U.S. RADIOPHARMACEUTICALS MARKET FOR LUNG SCAN, BY TYPE, 2014–2023 (USD MILLION)
TABLE 73 U.S. RADIOPHARMACEUTICALS MARKET FOR WHITE BLOOD CELL SCAN, BY TYPE, 2014–2023 (USD MILLION)
TABLE 74 U.S. RADIOPHARMACEUTICAL MARKET, BY APPLICATION, 2014–2023 (USD MILLION)
TABLE 75 U.S. RADIOPHARMACEUTICAL MARKET FOR ONCOLOGY, BY TYPE, 2014–2023 (USD MILLION)
TABLE 76 U.S. RADIOPHARMACEUTICAL MARKET FOR CARDIOLOGY, BY TYPE, 2014–2023 (USD MILLION)
TABLE 77 U.S. RADIOPHARMACEUTICAL MARKET FOR NEUROLOGY, BY TYPE, 2014–2023 (USD MILLION)
TABLE 78 U.S. RADIOPHARMACEUTICAL MARKET FOR UROLOGY, BY TYPE, 2014–2023 (USD MILLION)
TABLE 79 U.S. RADIOPHARMACEUTICAL MARKET, BY ROUTE OF ADMINISTRATION, 2014–2023 (USD MILLION)
TABLE 80 U.S. RADIOPHARMACEUTICAL MARKET, BY END-USER, 2014–2023 (USD MILLION)
TABLE 81 CANADA RADIOPHARMACEUTICAL MARKET, BY TYPE, 2014–2023 (USD MILLION)
TABLE 82 CANADA RADIOPHARMACEUTICAL MARKET FOR DIAGNOSTIC, BY TYPE, 2014–2023 (USD MILLION)
TABLE 83 CANADA RADIOPHARMACEUTICAL MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION)
TABLE 84 CANADA RADIOPHARMACEUTICAL MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION)
TABLE 85 CANADA RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC, BY TYPE, 2014–2023 (USD MILLION)
TABLE 86 CANADA RADIOPHARMACEUTICAL MARKET FOR BETA EMITTERS, BY TYPE, 2014–2023 (USD MILLION) 91
TABLE 87 CANADA RADIOPHARMACEUTICAL MARKET FOR BRACHYTHERAPY, BY TYPE, 2014–2023 (USD MILLION) 91
TABLE 88 CANADA RADIOPHARMACEUTICALS MARKET, BY TYPE OF TEST, 2014–2023 (USD MILLION) 92
TABLE 89 CANADA RADIOPHARMACEUTICALS MARKET FOR BONE SCAN, BY TYPE, 2014–2023 (USD MILLION) 92
TABLE 90 CANADA RADIOPHARMACEUTICALS MARKET FOR MYOCARDIAL PERFUSION SCAN, BY TYPE, 2014–2023 (USD MILLION) 93
TABLE 91 CANADA RADIOPHARMACEUTICALS MARKET FOR LUNG SCAN, BY TYPE, 2014–2023 (USD MILLION) 93
TABLE 92 CANADA RADIOPHARMACEUTICALS MARKET FOR WHITE BLOOD CELL SCAN, BY TYPE, 2014–2023 (USD MILLION) 93
TABLE 93 CANADA RADIOPHARMACEUTICAL MARKET, BY APPLICATION, 2014–2023 (USD MILLION) 94
TABLE 94 CANADA RADIOPHARMACEUTICAL MARKET FOR ONCOLOGY, BY TYPE, 2014–2023 (USD MILLION) 94
TABLE 95 CANADA RADIOPHARMACEUTICAL MARKET FOR CARDIOLOGY, BY TYPE, 2014–2023 (USD MILLION) 94
TABLE 96 CANADA RADIOPHARMACEUTICAL MARKET FOR NEUROLOGY, BY TYPE, 2014–2023 (USD MILLION) 95
TABLE 97 CANADA RADIOPHARMACEUTICAL MARKET FOR UROLOGY, BY TYPE, 2014–2023 (USD MILLION) 95
TABLE 98 CANADA RADIOPHARMACEUTICAL MARKET, BY ROUTE OF ADMINISTRATION, 2014–2023 (USD MILLION) 95
TABLE 99 CANADA RADIOPHARMACEUTICAL MARKET, BY END-USER, 2014–2023 (USD MILLION) 96
TABLE 100 SOUTH AMERICA RADIOPHARMACEUTICAL MARKET, BY TYPE, 2014–2023 (USD MILLION) 96
TABLE 101 SOUTH AMERICA RADIOPHARMACEUTICAL MARKET FOR DIAGNOSTIC, BY TYPE, 2014–2023 (USD MILLION) 96
TABLE 102 SOUTH AMERICA RADIOPHARMACEUTICAL MARKET FOR SPECT RADIOPHARMACEUTICAL, BY TYPE,
2014–2023 (USD MILLION) 97
TABLE 103 SOUTH AMERICA RADIOPHARMACEUTICAL MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE,
2014–2023 (USD MILLION) 97
TABLE 104 SOUTH AMERICA RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC, BY TYPE, 2014–2023 (USD MILLION) 97
TABLE 105 SOUTH AMERICA RADIOPHARMACEUTICAL MARKET FOR BETA EMITTERS, BY TYPE, 2014–2023 (USD MILLION) 98
TABLE 106 SOUTH AMERICA RADIOPHARMACEUTICAL MARKET FOR BRACHYTHERAPY, BY TYPE, 2014–2023 (USD MILLION) 98
TABLE 107 SOUTH AMERICA RADIOPHARMACEUTICALS MARKET, BY TYPE OF TEST, 2014–2023 (USD MILLION) 99
TABLE 108 SOUTH AMERICA RADIOPHARMACEUTICALS MARKET FOR BONE SCAN, BY TYPE, 2014–2023 (USD MILLION) 99
TABLE 109 SOUTH AMERICA RADIOPHARMACEUTICALS MARKET FOR MYOCARDIAL PERFUSION SCAN, BY TYPE,
2014–2023 (USD MILLION) 100
TABLE 110 SOUTH AMERICA RADIOPHARMACEUTICALS MARKET FOR LUNG SCAN, BY TYPE, 2014–2023 (USD MILLION) 100
TABLE 111 SOUTH AMERICA RADIOPHARMACEUTICALS MARKET FOR WHITE BLOOD CELL SCAN, BY TYPE, 2014–2023 (USD MILLION) 100
TABLE 112 SOUTH AMERICA RADIOPHARMACEUTICAL MARKET, BY APPLICATION, 2014–2023 (USD MILLION) 101
TABLE 113 SOUTH AMERICA RADIOPHARMACEUTICAL MARKET FOR ONCOLOGY, BY TYPE, 2014–2023 (USD MILLION) 101
TABLE 114 SOUTH AMERICA RADIOPHARMACEUTICAL MARKET FOR CARDIOLOGY, BY TYPE, 2014–2023 (USD MILLION) 101
TABLE 115 SOUTH AMERICA RADIOPHARMACEUTICAL MARKET FOR NEUROLOGY, BY TYPE, 2014–2023 (USD MILLION) 102
TABLE 116 SOUTH AMERICA RADIOPHARMACEUTICAL MARKET FOR UROLOGY, BY TYPE, 2014–2023 (USD MILLION) 102
TABLE 117 SOUTH AMERICA RADIOPHARMACEUTICAL MARKET, BY ROUTE OF ADMINISTRATION, 2014–2023 (USD MILLION) 102
TABLE 118 SOUTH AMERICA RADIOPHARMACEUTICAL MARKET, BY END-USER, 2014–2023 (USD MILLION) 103
TABLE 119 EUROPE RADIOPHARMACEUTICAL MARKET, BY COUNTRY, 2014–2023 (USD MILLION) 103
TABLE 120 EUROPE RADIOPHARMACEUTICAL MARKET, BY TYPE, 2014–2023 (USD MILLION) 104
TABLE 121 EUROPE RADIOPHARMACEUTICAL MARKET FOR DIAGNOSTIC, BY TYPE, 2014–2023 (USD MILLION) 104
TABLE 122 EUROPE RADIOPHARMACEUTICAL MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION) 105
TABLE 123 EUROPE RADIOPHARMACEUTICAL MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION) 105
TABLE 124 EUROPE RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC, BY TYPE, 2014–2023 (USD MILLION) 105
TABLE 125 EUROPE RADIOPHARMACEUTICAL MARKET FOR BETA EMITTERS, BY TYPE, 2014–2023 (USD MILLION) 106
TABLE 126 EUROPE RADIOPHARMACEUTICAL MARKET FOR BRACHYTHERAPY, BY TYPE, 2014–2023 (USD MILLION) 106
TABLE 127 EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE OF TEST, 2014–2023 (USD MILLION) 107
TABLE 128 EUROPE RADIOPHARMACEUTICALS MARKET FOR BONE SCAN, BY TYPE, 2014–2023 (USD MILLION) 107
TABLE 129 EUROPE RADIOPHARMACEUTICALS MARKET FOR MYOCARDIAL PERFUSION SCAN, BY TYPE, 2014–2023 (USD MILLION) 108
TABLE 130 EUROPE RADIOPHARMACEUTICALS MARKET FOR LUNG SCAN, BY TYPE, 2014–2023 (USD MILLION) 108
TABLE 131 EUROPE RADIOPHARMACEUTICALS MARKET FOR WHITE BLOOD CELL SCAN, BY TYPE, 2014–2023 (USD MILLION) 108
TABLE 132 EUROPE RADIOPHARMACEUTICAL MARKET, BY APPLICATION, 2014–2023 (USD MILLION) 109
TABLE 133 EUROPE RADIOPHARMACEUTICAL MARKET FOR ONCOLOGY, BY TYPE, 2014–2023 (USD MILLION) 109
TABLE 134 EUROPE RADIOPHARMACEUTICAL MARKET FOR CARDIOLOGY, BY TYPE, 2014–2023 (USD MILLION) 109
TABLE 135 EUROPE RADIOPHARMACEUTICAL MARKET FOR NEUROLOGY, BY TYPE, 2014–2023 (USD MILLION) 110
TABLE 136 EUROPE RADIOPHARMACEUTICAL MARKET FOR UROLOGY, BY TYPE, 2014–2023 (USD MILLION) 110
TABLE 137 EUROPE RADIOPHARMACEUTICAL MARKET, BY ROUTE OF ADMINISTRATION, 2014–2023 (USD MILLION) 110
TABLE 138 EUROPE RADIOPHARMACEUTICAL MARKET, BY END-USER, 2014–2023 (USD MILLION) 111
TABLE 139 GERMANY RADIOPHARMACEUTICAL MARKET, BY TYPE, 2014–2023 (USD MILLION) 111
TABLE 140 GERMANY RADIOPHARMACEUTICAL MARKET FOR DIAGNOSTIC, BY TYPE, 2014–2023 (USD MILLION) 111
TABLE 141 GERMANY RADIOPHARMACEUTICAL MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION) 112
TABLE 142 GERMANY RADIOPHARMACEUTICAL MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION) 112
TABLE 143 GERMANY RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC, BY TYPE, 2014–2023 (USD MILLION) 112
TABLE 144 GERMANY RADIOPHARMACEUTICAL MARKET FOR BETA EMITTERS, BY TYPE, 2014–2023 (USD MILLION) 113
TABLE 145 GERMANY RADIOPHARMACEUTICAL MARKET FOR BRACHYTHERAPY, BY TYPE, 2014–2023 (USD MILLION) 113
TABLE 146 GERMANY RADIOPHARMACEUTICALS MARKET, BY TYPE OF TEST, 2014–2023 (USD MILLION) 114
TABLE 147 GERMANY RADIOPHARMACEUTICALS MARKET FOR BONE SCAN, BY TYPE, 2014–2023 (USD MILLION) 114
TABLE 148 GERMANY RADIOPHARMACEUTICALS MARKET FOR MYOCARDIAL PERFUSION SCAN, BY TYPE, 2014–2023 (USD MILLION) 115
TABLE 149 GERMANY RADIOPHARMACEUTICALS MARKET FOR LUNG SCAN, BY TYPE, 2014–2023 (USD MILLION) 115
TABLE 150 GERMANY RADIOPHARMACEUTICALS MARKET FOR WHITE BLOOD CELL SCAN, BY TYPE, 2014–2023 (USD MILLION) 115
TABLE 151 GERMANY RADIOPHARMACEUTICAL MARKET, BY APPLICATION, 2014–2023 (USD MILLION) 116
TABLE 152 GERMANY RADIOPHARMACEUTICAL MARKET FOR ONCOLOGY, BY TYPE, 2014–2023 (USD MILLION) 116
TABLE 153 GERMANY RADIOPHARMACEUTICAL MARKET FOR CARDIOLOGY, BY TYPE, 2014–2023 (USD MILLION) 116
TABLE 154 GERMANY RADIOPHARMACEUTICAL MARKET FOR NEUROLOGY, BY TYPE, 2014–2023 (USD MILLION) 117
TABLE 155 GERMANY RADIOPHARMACEUTICAL MARKET FOR UROLOGY, BY TYPE, 2014–2023 (USD MILLION) 117
TABLE 156 GERMANY RADIOPHARMACEUTICAL MARKET, BY ROUTE OF ADMINISTRATION, 2014–2023 (USD MILLION) 117
TABLE 157 GERMANY RADIOPHARMACEUTICAL MARKET, BY END-USER, 2014–2023 (USD MILLION) 118
TABLE 158 FRANCE RADIOPHARMACEUTICAL MARKET, BY TYPE, 2014–2023 (USD MILLION) 118
TABLE 159 FRANCE RADIOPHARMACEUTICAL MARKET FOR DIAGNOSTIC, BY TYPE, 2014–2023 (USD MILLION) 118
TABLE 160 FRANCE RADIOPHARMACEUTICAL MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION) 119
TABLE 161 FRANCE RADIOPHARMACEUTICAL MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION) 119
TABLE 162 FRANCE RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC, BY TYPE, 2014–2023 (USD MILLION) 119
TABLE 163 FRANCE RADIOPHARMACEUTICAL MARKET FOR BETA EMITTERS, BY TYPE, 2014–2023 (USD MILLION) 120
TABLE 164 FRANCE RADIOPHARMACEUTICAL MARKET FOR BRACHYTHERAPY, BY TYPE, 2014–2023 (USD MILLION) 120
TABLE 165 FRANCE RADIOPHARMACEUTICALS MARKET, BY TYPE OF TEST, 2014–2023 (USD MILLION) 121
TABLE 166 FRANCE RADIOPHARMACEUTICALS MARKET FOR BONE SCAN, BY TYPE, 2014–2023 (USD MILLION) 121
TABLE 167 FRANCE RADIOPHARMACEUTICALS MARKET FOR MYOCARDIAL PERFUSION SCAN, BY TYPE, 2014–2023 (USD MILLION) 122
TABLE 168 FRANCE RADIOPHARMACEUTICALS MARKET FOR LUNG SCAN, BY TYPE, 2014–2023 (USD MILLION) 122
TABLE 169 FRANCE RADIOPHARMACEUTICALS MARKET FOR WHITE BLOOD CELL SCAN, BY TYPE, 2014–2023 (USD MILLION) 122
TABLE 170 FRANCE RADIOPHARMACEUTICAL MARKET, BY APPLICATION, 2014–2023 (USD MILLION) 123
TABLE 171 FRANCE RADIOPHARMACEUTICAL MARKET FOR ONCOLOGY, BY TYPE, 2014–2023 (USD MILLION) 123
TABLE 172 FRANCE RADIOPHARMACEUTICAL MARKET FOR CARDIOLOGY, BY TYPE, 2014–2023 (USD MILLION) 123
TABLE 173 FRANCE RADIOPHARMACEUTICAL MARKET FOR NEUROLOGY, BY TYPE, 2014–2023 (USD MILLION) 124
TABLE 174 FRANCE RADIOPHARMACEUTICAL MARKET FOR UROLOGY, BY TYPE, 2014–2023 (USD MILLION) 124
TABLE 175 FRANCE RADIOPHARMACEUTICAL MARKET, BY ROUTE OF ADMINISTRATION, 2014–2023 (USD MILLION) 124
TABLE 176 FRANCE RADIOPHARMACEUTICAL MARKET, BY END-USER, 2014–2023 (USD MILLION) 125
TABLE 177 U.K. RADIOPHARMACEUTICAL MARKET, BY TYPE, 2014–2023 (USD MILLION) 125
TABLE 178 U.K. RADIOPHARMACEUTICAL MARKET FOR DIAGNOSTIC, BY TYPE, 2014–2023 (USD MILLION) 125
TABLE 179 U.K. RADIOPHARMACEUTICAL MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION) 126
TABLE 180 U.K. RADIOPHARMACEUTICAL MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION) 126
TABLE 181 U.K. RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC, BY TYPE, 2014–2023 (USD MILLION) 126
TABLE 182 U.K. RADIOPHARMACEUTICAL MARKET FOR BETA EMITTERS, BY TYPE, 2014–2023 (USD MILLION) 127
TABLE 183 U.K. RADIOPHARMACEUTICAL MARKET FOR BRACHYTHERAPY, BY TYPE, 2014–2023 (USD MILLION) 127
TABLE 184 U.K. RADIOPHARMACEUTICALS MARKET, BY TYPE OF TEST, 2014–2023 (USD MILLION) 128
TABLE 185 U.K. RADIOPHARMACEUTICALS MARKET FOR BONE SCAN, BY TYPE, 2014–2023 (USD MILLION) 128
TABLE 186 U.K. RADIOPHARMACEUTICALS MARKET FOR MYOCARDIAL PERFUSION SCAN, BY TYPE, 2014–2023 (USD MILLION) 129
TABLE 187 U.K. RADIOPHARMACEUTICALS MARKET FOR LUNG SCAN, BY TYPE, 2014–2023 (USD MILLION) 129
TABLE 188 U.K. RADIOPHARMACEUTICALS MARKET FOR WHITE BLOOD CELL SCAN, BY TYPE, 2014–2023 (USD MILLION) 129
TABLE 189 U.K. RADIOPHARMACEUTICAL MARKET, BY APPLICATION, 2014–2023 (USD MILLION) 130
TABLE 190 U.K. RADIOPHARMACEUTICAL MARKET FOR ONCOLOGY, BY TYPE, 2014–2023 (USD MILLION) 130
TABLE 191 U.K. RADIOPHARMACEUTICAL MARKET FOR CARDIOLOGY, BY TYPE, 2014–2023 (USD MILLION) 130
TABLE 192 U.K. RADIOPHARMACEUTICAL MARKET FOR NEUROLOGY, BY TYPE, 2014–2023 (USD MILLION) 131
TABLE 193 U.K. RADIOPHARMACEUTICAL MARKET FOR UROLOGY, BY TYPE, 2014–2023 (USD MILLION) 131
TABLE 194 U.K. RADIOPHARMACEUTICAL MARKET, BY ROUTE OF ADMINISTRATION, 2014–2023 (USD MILLION) 131
TABLE 195 U.K. RADIOPHARMACEUTICAL MARKET, BY END-USER, 2014–2023 (USD MILLION) 132
TABLE 196 ITALY RADIOPHARMACEUTICAL MARKET, BY TYPE, 2014–2023 (USD MILLION) 132
TABLE 197 ITALY RADIOPHARMACEUTICAL MARKET FOR DIAGNOSTIC, BY TYPE, 2014–2023 (USD MILLION) 132
TABLE 198 ITALY RADIOPHARMACEUTICAL MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION) 133
TABLE 199 ITALY RADIOPHARMACEUTICAL MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION) 133
TABLE 200 ITALY RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC, BY TYPE, 2014–2023 (USD MILLION) 133
TABLE 201 ITALY RADIOPHARMACEUTICAL MARKET FOR BETA EMITTERS, BY TYPE, 2014–2023 (USD MILLION) 134
TABLE 202 ITALY RADIOPHARMACEUTICAL MARKET FOR BRACHYTHERAPY, BY TYPE, 2014–2023 (USD MILLION) 134
TABLE 203 ITALY RADIOPHARMACEUTICALS MARKET, BY TYPE OF TEST, 2014–2023 (USD MILLION) 135
TABLE 204 ITALY RADIOPHARMACEUTICALS MARKET FOR BONE SCAN, BY TYPE, 2014–2023 (USD MILLION) 135
TABLE 205 ITALY RADIOPHARMACEUTICALS MARKET FOR MYOCARDIAL PERFUSION SCAN, BY TYPE, 2014–2023 (USD MILLION) 136
TABLE 206 ITALY RADIOPHARMACEUTICALS MARKET FOR LUNG SCAN, BY TYPE, 2014–2023 (USD MILLION) 136
TABLE 207 ITALY RADIOPHARMACEUTICALS MARKET FOR WHITE BLOOD CELL SCAN, BY TYPE, 2014–2023 (USD MILLION) 136
TABLE 208 ITALY RADIOPHARMACEUTICAL MARKET, BY APPLICATION, 2014–2023 (USD MILLION) 137
TABLE 209 ITALY RADIOPHARMACEUTICAL MARKET FOR ONCOLOGY, BY TYPE, 2014–2023 (USD MILLION) 137
TABLE 210 ITALY RADIOPHARMACEUTICAL MARKET FOR CARDIOLOGY, BY TYPE, 2014–2023 (USD MILLION) 137
TABLE 211 ITALY RADIOPHARMACEUTICAL MARKET FOR NEUROLOGY, BY TYPE, 2014–2023 (USD MILLION) 138
TABLE 212 ITALY RADIOPHARMACEUTICAL MARKET FOR UROLOGY, BY TYPE, 2014–2023 (USD MILLION) 138
TABLE 213 ITALY RADIOPHARMACEUTICAL MARKET, BY ROUTE OF ADMINISTRATION, 2014–2023 (USD MILLION) 138
TABLE 214 ITALY RADIOPHARMACEUTICAL MARKET, BY END-USER, 2014–2023 (USD MILLION) 139
TABLE 215 SPAIN RADIOPHARMACEUTICAL MARKET, BY TYPE, 2014–2023 (USD MILLION) 139
TABLE 216 SPAIN RADIOPHARMACEUTICAL MARKET FOR DIAGNOSTIC, BY TYPE, 2014–2023 (USD MILLION) 139
TABLE 217 SPAIN RADIOPHARMACEUTICAL MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION) 140
TABLE 218 SPAIN RADIOPHARMACEUTICAL MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION) 140
TABLE 219 SPAIN RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC, BY TYPE, 2014–2023 (USD MILLION) 140
TABLE 220 SPAIN RADIOPHARMACEUTICAL MARKET FOR BETA EMITTERS, BY TYPE, 2014–2023 (USD MILLION) 141
TABLE 221 SPAIN RADIOPHARMACEUTICAL MARKET FOR BRACHYTHERAPY, BY TYPE, 2014–2023 (USD MILLION) 141
TABLE 222 SPAIN RADIOPHARMACEUTICALS MARKET, BY TYPE OF TEST, 2014–2023 (USD MILLION) 142
TABLE 223 SPAIN RADIOPHARMACEUTICALS MARKET FOR BONE SCAN, BY TYPE, 2014–2023 (USD MILLION) 142
TABLE 224 SPAIN RADIOPHARMACEUTICALS MARKET FOR MYOCARDIAL PERFUSION SCAN, BY TYPE, 2014–2023 (USD MILLION) 143
TABLE 225 SPAIN RADIOPHARMACEUTICALS MARKET FOR LUNG SCAN, BY TYPE, 2014–2023 (USD MILLION) 143
TABLE 226 SPAIN RADIOPHARMACEUTICALS MARKET FOR WHITE BLOOD CELL SCAN, BY TYPE, 2014–2023 (USD MILLION) 143
TABLE 227 SPAIN RADIOPHARMACEUTICAL MARKET, BY APPLICATION, 2014–2023 (USD MILLION) 144
TABLE 228 SPAIN RADIOPHARMACEUTICAL MARKET FOR ONCOLOGY, BY TYPE, 2014–2023 (USD MILLION) 144
TABLE 229 SPAIN RADIOPHARMACEUTICAL MARKET FOR CARDIOLOGY, BY TYPE, 2014–2023 (USD MILLION) 144
TABLE 230 SPAIN RADIOPHARMACEUTICAL MARKET FOR NEUROLOGY, BY TYPE, 2014–2023 (USD MILLION) 145
TABLE 231 SPAIN RADIOPHARMACEUTICAL MARKET FOR UROLOGY, BY TYPE, 2014–2023 (USD MILLION) 145
TABLE 232 SPAIN RADIOPHARMACEUTICAL MARKET, BY ROUTE OF ADMINISTRATION, 2014–2023 (USD MILLION) 145
TABLE 233 SPAIN RADIOPHARMACEUTICAL MARKET, BY END-USER, 2014–2023 (USD MILLION) 146
TABLE 234 REST OF WESTERN EUROPE RADIOPHARMACEUTICAL MARKET, BY TYPE, 2014–2023 (USD MILLION) 146
TABLE 235 REST OF WESTERN EUROPE RADIOPHARMACEUTICAL MARKET FOR DIAGNOSTIC, BY TYPE, 2014–2023 (USD MILLION) 146
TABLE 236 REST OF WESTERN EUROPE RADIOPHARMACEUTICAL MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE,
2014–2023 (USD MILLION) 147
TABLE 237 REST OF WESTERN EUROPE RADIOPHARMACEUTICAL MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE,
2014–2023 (USD MILLION) 147
TABLE 238 REST OF WESTERN EUROPE RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC, BY TYPE, 2014–2023 (USD MILLION) 147
TABLE 239 REST OF WESTERN EUROPE RADIOPHARMACEUTICAL MARKET FOR BETA EMITTERS, BY TYPE, 2014–2023 (USD MILLION) 148
TABLE 240 REST OF WESTERN EUROPE RADIOPHARMACEUTICAL MARKET FOR BRACHYTHERAPY, BY TYPE, 2014–2023 (USD MILLION) 148
TABLE 241 REST OF WESTERN EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE OF TEST, 2014–2023 (USD MILLION) 149
TABLE 242 REST OF WESTERN EUROPE RADIOPHARMACEUTICALS MARKET FOR BONE SCAN, BY TYPE, 2014–2023 (USD MILLION) 149
TABLE 243 REST OF WESTERN EUROPE RADIOPHARMACEUTICALS MARKET FOR MYOCARDIAL PERFUSION SCAN, BY TYPE,
2014–2023 (USD MILLION) 150
TABLE 244 REST OF WESTERN EUROPE RADIOPHARMACEUTICALS MARKET FOR LUNG SCAN, BY TYPE, 2014–2023 (USD MILLION) 150
TABLE 245 REST OF WESTERN EUROPE RADIOPHARMACEUTICALS MARKET FOR WHITE BLOOD CELL SCAN, BY TYPE,
2014–2023 (USD MILLION) 150
TABLE 246 REST OF WESTERN EUROPE RADIOPHARMACEUTICAL MARKET, BY APPLICATION, 2014–2023 (USD MILLION) 151
TABLE 247 REST OF WESTERN EUROPE RADIOPHARMACEUTICAL MARKET FOR ONCOLOGY, BY TYPE, 2014–2023 (USD MILLION) 151
TABLE 248 REST OF WESTERN EUROPE RADIOPHARMACEUTICAL MARKET FOR CARDIOLOGY, BY TYPE, 2014–2023 (USD MILLION) 151
TABLE 249 REST OF WESTERN EUROPE RADIOPHARMACEUTICAL MARKET FOR NEUROLOGY, BY TYPE, 2014–2023 (USD MILLION) 152
TABLE 250 REST OF WESTERN EUROPE RADIOPHARMACEUTICAL MARKET FOR UROLOGY, BY TYPE, 2014–2023 (USD MILLION) 152
TABLE 251 REST OF WESTERN EUROPE RADIOPHARMACEUTICAL MARKET, BY ROUTE OF ADMINISTRATION, 2014–2023 (USD MILLION) 152
TABLE 252 REST OF WESTERN EUROPE RADIOPHARMACEUTICAL MARKET, BY END-USER, 2014–2023 (USD MILLION) 153
TABLE 253 EASTERN EUROPE RADIOPHARMACEUTICAL MARKET, BY TYPE, 2014–2023 (USD MILLION) 153
TABLE 254 EASTERN EUROPE RADIOPHARMACEUTICAL MARKET FOR DIAGNOSTIC, BY TYPE, 2014–2023 (USD MILLION) 153
TABLE 255 EASTERN EUROPE RADIOPHARMACEUTICAL MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE,
2014–2023 (USD MILLION) 154
TABLE 256 EASTERN EUROPE RADIOPHARMACEUTICAL MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE,
2014–2023 (USD MILLION) 154
TABLE 257 EASTERN EUROPE RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC, BY TYPE, 2014–2023 (USD MILLION) 154
TABLE 258 EASTERN EUROPE RADIOPHARMACEUTICAL MARKET FOR BETA EMITTERS, BY TYPE, 2014–2023 (USD MILLION) 155
TABLE 259 EASTERN EUROPE RADIOPHARMACEUTICAL MARKET FOR BRACHYTHERAPY, BY TYPE, 2014–2023 (USD MILLION) 155
TABLE 260 EASTERN EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE OF TEST, 2014–2023 (USD MILLION) 156
TABLE 261 EASTERN EUROPE RADIOPHARMACEUTICALS MARKET FOR BONE SCAN, BY TYPE, 2014–2023 (USD MILLION) 156
TABLE 262 EASTERN EUROPE RADIOPHARMACEUTICALS MARKET FOR MYOCARDIAL PERFUSION SCAN, BY TYPE,
2014–2023 (USD MILLION) 157
TABLE 263 EASTERN EUROPE RADIOPHARMACEUTICALS MARKET FOR LUNG SCAN, BY TYPE, 2014–2023 (USD MILLION) 157
TABLE 264 EASTERN EUROPE RADIOPHARMACEUTICALS MARKET FOR WHITE BLOOD CELL SCAN, BY TYPE, 2014–2023 (USD MILLION) 157
TABLE 265 EASTERN EUROPE RADIOPHARMACEUTICAL MARKET, BY APPLICATION, 2014–2023 (USD MILLION) 158
TABLE 266 EASTERN EUROPE RADIOPHARMACEUTICAL MARKET FOR ONCOLOGY, BY TYPE, 2014–2023 (USD MILLION) 158
TABLE 267 EASTERN EUROPE RADIOPHARMACEUTICAL MARKET FOR CARDIOLOGY, BY TYPE, 2014–2023 (USD MILLION) 158
TABLE 268 EASTERN EUROPE RADIOPHARMACEUTICAL MARKET FOR NEUROLOGY, BY TYPE, 2014–2023 (USD MILLION) 159
TABLE 269 EASTERN EUROPE RADIOPHARMACEUTICAL MARKET FOR UROLOGY, BY TYPE, 2014–2023 (USD MILLION) 159
TABLE 270 EASTERN EUROPE RADIOPHARMACEUTICAL MARKET, BY ROUTE OF ADMINISTRATION, 2014–2023 (USD MILLION) 159
TABLE 271 EASTERN EUROPE RADIOPHARMACEUTICAL MARKET, BY END-USER, 2014–2023 (USD MILLION) 160
TABLE 272 ASIA PACIFIC RADIOPHARMACEUTICAL MARKET, BY COUNTRY, 2014–2023 (USD MILLION) 160
TABLE 273 ASIA PACIFIC RADIOPHARMACEUTICAL MARKET, BY TYPE, 2014–2023 (USD MILLION) 161
TABLE 274 ASIA PACIFIC RADIOPHARMACEUTICAL MARKET FOR DIAGNOSTIC, BY TYPE, 2014–2023 (USD MILLION) 161
TABLE 275 ASIA PACIFIC RADIOPHARMACEUTICAL MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION) 161
TABLE 276 ASIA PACIFIC RADIOPHARMACEUTICAL MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION) 162
TABLE 277 ASIA PACIFIC RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC, BY TYPE, 2014–2023 (USD MILLION) 162
TABLE 278 ASIA PACIFIC RADIOPHARMACEUTICAL MARKET FOR BETA EMITTERS, BY TYPE, 2014–2023 (USD MILLION) 162
TABLE 279 ASIA PACIFIC RADIOPHARMACEUTICAL MARKET FOR BRACHYTHERAPY, BY TYPE, 2014–2023 (USD MILLION) 163
TABLE 280 ASIA PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE OF TEST, 2014–2023 (USD MILLION) 163
TABLE 281 ASIA PACIFIC RADIOPHARMACEUTICALS MARKET FOR BONE SCAN, BY TYPE, 2014–2023 (USD MILLION) 164
TABLE 282 ASIA PACIFIC RADIOPHARMACEUTICALS MARKET FOR MYOCARDIAL PERFUSION SCAN, BY TYPE, 2014–2023 (USD MILLION) 164
TABLE 283 ASIA PACIFIC RADIOPHARMACEUTICALS MARKET FOR LUNG SCAN, BY TYPE, 2014–2023 (USD MILLION) 164
TABLE 284 ASIA PACIFIC RADIOPHARMACEUTICALS MARKET FOR WHITE BLOOD CELL SCAN, BY TYPE, 2014–2023 (USD MILLION) 165
TABLE 285 ASIA PACIFIC RADIOPHARMACEUTICAL MARKET, BY APPLICATION, 2014–2023 (USD MILLION) 165
TABLE 286 ASIA PACIFIC RADIOPHARMACEUTICAL MARKET FOR ONCOLOGY, BY TYPE, 2014–2023 (USD MILLION) 165
TABLE 287 ASIA PACIFIC RADIOPHARMACEUTICAL MARKET FOR CARDIOLOGY, BY TYPE, 2014–2023 (USD MILLION) 166
TABLE 288 ASIA PACIFIC RADIOPHARMACEUTICAL MARKET FOR NEUROLOGY, BY TYPE, 2014–2023 (USD MILLION) 166
TABLE 289 ASIA PACIFIC RADIOPHARMACEUTICAL MARKET FOR UROLOGY, BY TYPE, 2014–2023 (USD MILLION) 166
TABLE 290 ASIA PACIFIC RADIOPHARMACEUTICAL MARKET, BY ROUTE OF ADMINISTRATION, 2014–2023 (USD MILLION) 167
TABLE 291 ASIA PACIFIC RADIOPHARMACEUTICAL MARKET, BY END-USER, 2014–2023 (USD MILLION) 167
TABLE 292 JAPAN RADIOPHARMACEUTICAL MARKET, BY TYPE, 2014–2023 (USD MILLION) 168
TABLE 293 JAPAN RADIOPHARMACEUTICAL MARKET FOR DIAGNOSTIC, BY TYPE, 2014–2023 (USD MILLION) 168
TABLE 294 JAPAN RADIOPHARMACEUTICAL MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION) 168
TABLE 295 JAPAN RADIOPHARMACEUTICAL MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION) 169
TABLE 296 JAPAN RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC, BY TYPE, 2014–2023 (USD MILLION) 169
TABLE 297 JAPAN RADIOPHARMACEUTICAL MARKET FOR BETA EMITTERS, BY TYPE, 2014–2023 (USD MILLION) 169
TABLE 298 JAPAN RADIOPHARMACEUTICAL MARKET FOR BRACHYTHERAPY, BY TYPE, 2014–2023 (USD MILLION) 170
TABLE 299 JAPAN RADIOPHARMACEUTICALS MARKET, BY TYPE OF TEST, 2014–2023 (USD MILLION) 170
TABLE 300 JAPAN RADIOPHARMACEUTICALS MARKET FOR BONE SCAN, BY TYPE, 2014–2023 (USD MILLION) 171
TABLE 301 JAPAN RADIOPHARMACEUTICALS MARKET FOR MYOCARDIAL PERFUSION SCAN, BY TYPE, 2014–2023 (USD MILLION) 171
TABLE 302 JAPAN RADIOPHARMACEUTICALS MARKET FOR LUNG SCAN, BY TYPE, 2014–2023 (USD MILLION) 171
TABLE 303 JAPAN RADIOPHARMACEUTICALS MARKET FOR WHITE BLOOD CELL SCAN, BY TYPE, 2014–2023 (USD MILLION) 172
TABLE 304 JAPAN RADIOPHARMACEUTICAL MARKET, BY APPLICATION, 2014–2023 (USD MILLION) 172
TABLE 305 JAPAN RADIOPHARMACEUTICAL MARKET FOR ONCOLOGY, BY TYPE, 2014–2023 (USD MILLION) 172
TABLE 306 JAPAN RADIOPHARMACEUTICAL MARKET FOR CARDIOLOGY, BY TYPE, 2014–2023 (USD MILLION) 173
TABLE 307 JAPAN RADIOPHARMACEUTICAL MARKET FOR NEUROLOGY, BY TYPE, 2014–2023 (USD MILLION) 173
TABLE 308 JAPAN RADIOPHARMACEUTICAL MARKET FOR UROLOGY, BY TYPE, 2014–2023 (USD MILLION) 173
TABLE 309 JAPAN RADIOPHARMACEUTICAL MARKET, BY ROUTE OF ADMINISTRATION, 2014–2023 (USD MILLION) 174
TABLE 310 JAPAN RADIOPHARMACEUTICAL MARKET, BY END-USER, 2014–2023 (USD MILLION) 174
TABLE 311 CHINA RADIOPHARMACEUTICAL MARKET, BY TYPE, 2014–2023 (USD MILLION) 175
TABLE 312 CHINA RADIOPHARMACEUTICAL MARKET FOR DIAGNOSTIC, BY TYPE, 2014–2023 (USD MILLION) 175
TABLE 313 CHINA RADIOPHARMACEUTICAL MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION) 175
TABLE 314 CHINA RADIOPHARMACEUTICAL MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2014–2023 (USD MILLION) 176
TABLE 315 CHINA RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC, BY TYPE, 2014–2023 (USD MILLION) 176
TABLE 316 CHINA RADIOPHARMACEUTICAL MARKET FOR BETA EMITTERS, BY TYPE, 2014–2023 (USD MILLION) 176
TABLE 317 CHINA RADIOPHARMACEUTICAL MARKET FOR BRACHYTHERAPY, BY TYPE, 2014–2023 (USD MILLION) 177
TABLE 318 CHINA RADIOPHARMACEUTICALS MARKET, BY TYPE OF TEST, 2014–2023 (USD MILLION) 177
TABLE 319 CHINA RADIOPHARMACEUTICALS MARKET FOR BONE SCAN, BY TYPE, 2014–2023 (USD MILLION) 178
TABLE 320 CHINA RADIOPHARMACEUTICALS MARKET FOR MYOCARDIAL PERFUSION SCAN, BY TYPE, 2014–2023 (USD MILLION) 178
TABLE 321 CHINA RADIOPHARMACEUTICALS MARKET FOR LUNG SCAN, BY TYPE, 2014–2023 (USD MILLION) 178
TABLE 322 CHINA RADIOPHARMACEUTICALS MARKET FOR WHITE BLOOD CELL SCAN, BY TYPE, 2014–2023 (USD MILLION) 179
TABLE 323 CHINA RADIOPHARMACEUTICAL MARKET, BY APPLICATION, 2014–2023 (USD MILLION) 179
TABLE 324 CHINA RADIOPHARMACEUTICAL MARKET FOR ONCOLOGY, BY TYPE, 2014–2023 (USD MILLION) 179
TABLE 325 CHINA RADIOPHARMACEUTICAL MARKET FOR CARDIOLOGY, BY TYPE, 2014–2023 (USD MILLION) 180
TAB


List Of Figures


FIGURE 1 GLOBAL RADIOPHARMACEUTICAL MARKET: MARKET STRUCTURE
FIGURE 2 TOP-DOWN & BOTTOM-UP APPROACH
FIGURE 3 DRIVERS & RESTRAINTS: GLOBAL RADIOPHARMACEUTICAL MARKET
FIGURE 4 PORTERS FIVE FORCES MODEL
FIGURE 5 VALUE CHAIN: RADIOPHARMACEUTICAL MARKET
FIGURE 6 DIAGNOSIS PROCEDURE NUMBERS, 2014–20232014–2023 E (UNITS)
FIGURE 7 THERAPEUTIC PROCEDURE NUMBERS, 2014–20232014–2023 E (UNITS)
FIGURE 8 GLOBAL RADIOPHARMACEUTICAL MARKET, BY TYPE, 2016 & 2023 (USD MILLION)
FIGURE 9 GLOBAL RADIOPHARMACEUTICAL MARKET, BY TYPE OF TEST, 2016 & 2023 (USD MILLION)
FIGURE 10 GLOBAL RADIOPHARMACEUTICAL MARKET, BY APPLICATION, 2016 & 2023 (USD MILLION)
FIGURE 11 GLOBAL RADIOPHARMACEUTICAL MARKET, BY ROUTE OF ADMINISTRATION, 2016 & 2023 (USD MILLION)
FIGURE 12 GLOBAL RADIOPHARMACEUTICAL MARKET, BY END-USER, 2016 & 2023 (USD MILLION)
FIGURE 13 GLOBAL RADIOPHARMACEUTICAL MARKET, BY REGION, 2016 & 2023 (USD MILLION)
FIGURE 14 AMERICAS RADIOPHARMACEUTICAL MARKET, BY REGION, 2016 (%)
FIGURE 15 EUROPE RADIOPHARMACEUTICAL MARKET, BY COUNTRY, 2016 (%)
FIGURE 16 ASIA PACIFIC RADIOPHARMACEUTICAL MARKET, BY COUNTRY, 2016 (%)
FIGURE 17 MIDDLE EAST & AFRICA RADIOPHARMACEUTICAL MARKET, BY COUNTRY, 2016 (%)
FIGURE 18 GLOBAL RADIOPHARMACEUTICALS MARKET, COMPANY SHARE ANALYSIS 2016 (%)
FIGURE 19 GLOBAL RADIOPHARMACEUTICALS MARKET COMPETITIVE LANDSCAPE 2016 (%)


Global Yersinia Diagnostic Testing Market US, Europe, Japan--Supplier Shares, Volume and Sales Segment Forecasts, Competitive Analysis, Emerging Technologies, Instrumentation Review, Opportunities for Suppliers

The report presents a detailed analysis of the Yersinia diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Yersinia definition, epidemiology

USD 3850 View Report

Global Vibrio Diagnostic Testing Market, 2019-2023 US, Europe, Japan--Supplier Shares, Volume and Sales Segment Forecasts, Competitive Analysis, Emerging Technologies, Instrumentation Review, Opportunities for Suppliers

The report presents a detailed analysis of the Vibrio diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Vibrio definition, epidemiology

USD 3850 View Report

Global Radiopharmaceuticals Industry Market Research Report

Based on the Radiopharmaceuticals industrial chain, this report mainly elaborates the definition, types, applications and major players of Radiopharmaceuticals market in details. Deep analysis about market status (2014-2019), enterprise competition

USD 2960 View Report

Global Radiopharmaceuticals Market Research Report 2018

Radiopharmaceuticals Report by Material, Application, and Geography Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions, focusing on the main

USD 2850 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available